{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:16:08Z","timestamp":1792271768346,"version":"4.4.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pansclerotic morphea (PSM) is a rare skin disease characterized by progressive stiffening of the skin with or without the typical superficial skin changes usually seen in morphea (localized scleroderma). Standard therapy, consisting of a combination of systemic glucocorticoids and methotrexate or mycophenolate mofetil, does rarely stop disease progression, which may lead to severe cutaneous sclerosis and secondary contractures. Little is known about the efficacy of newer biologicals such as abatacept, a fusion protein antibody against CTLA-4, or tocilizumab, a fully humanized IL-6R antibody, in the treatment of this pathology. We present the case of an 8 years old girl with an unusual, progressive stiffening of the skin, which was eventually diagnosed as pansclerotic morphea. A treatment with systemic glucocorticoids and methotrexate combined with tocilizumab led to a good clinical response within 2 months after initiation. In this paper, we discuss differential diagnoses to be considered and this new promising treatment option based on a case review of the literature.<\/jats:p>","DOI":"10.3389\/fimmu.2021.656407","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T06:17:11Z","timestamp":1615270631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts"],"prefix":"10.3389","volume":"12","author":[{"given":"Sarah","family":"Vent\u00e9jou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Schwieger-Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Christen-Zaech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Schnider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Bogiatzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Morren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allerg Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/pde12279","article-title":"Pansclerotic morphea with features of eosinophilic fasciitis: distinct entities or part of a continuum?","volume":"31","author":"Odhav","year":"2014","journal-title":"Ped Dermatol"},{"key":"B3","first-page":"128","article-title":"Eosinophilic fasciitis in children frequently progress to scleroderma like fibrosis","volume":"20","author":"Farrington","year":"1993","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10067-009-1178-z","article-title":"Stiff skin syndrome versus scleredema: a report of two cases","volume":"28","author":"Azevedo","year":"2009","journal-title":"Clin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s004310051323","article-title":"Scleroderma-like syndrome in a child: eosinophilic fasciitis or scleredema adultorum?","volume":"159","author":"Huemer","year":"2000","journal-title":"Eur J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1001\/archderm.11811886","article-title":"Cutaneous and subcutaneous inflammatory sclerosis syndromes","volume":"118","author":"Doyle","year":"1982","journal-title":"Arch Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23ra20","DOI":"10.1126\/scitranslmed3000488","article-title":"Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome","volume":"2","author":"Loeys","year":"2010","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jaad.201601038","article-title":"Segmental stiff skin syndrome (SSS): a distinct clinical entity","volume":"75","author":"Myers","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","article-title":"Juvenile localized scleroderma: clinical and epidemiological features in 750 children","volume":"45","author":"Zulian","year":"2006","journal-title":"Int Study Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3899\/jrheum130029","article-title":"Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort","volume":"41","author":"Kim","year":"2014","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3389\/fimmu201900908","article-title":"Immunopathogenesis of pediatric localized scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts. insights from the fascinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cyto.201104001","article-title":"Cytokine profiles in localized scleroderma and relationship to clinical features","volume":"55","author":"Kurzinski","year":"2011","journal-title":"Cytokine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF01262331","article-title":"Demonstration of interleu-kin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma","volume":"287","author":"Ihn","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10067-017-3580-2","article-title":"Multiplex assessment of serum cytokine and chemokine levels in idiopathic morphea and vitamin K 1-induced morphea","volume":"36","author":"Cox","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5114\/pdia201548044","article-title":"Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma","volume":"33","author":"Budzy\u0144ska-W\u0142odarczyk","year":"2016","journal-title":"Postepi Dermatol Alergol"},{"key":"B17","first-page":"251","article-title":"The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis","volume":"36","author":"Alecu","year":"1998","journal-title":"Rom J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00296-019-04269-w","article-title":"Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review","volume":"39","author":"Soh","year":"2019","journal-title":"Rheumatol Int"},{"key":"B19","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphea: a hopeful therapy for refractory cases?","volume":"35","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma","volume":"2","author":"Foeldvari","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with tocilizumab","volume":"155","author":"Zang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience","volume":"50","author":"Castellv\u00ed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B23","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","volume-title":"Rheumatology","author":"Li","year":"2020"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.656407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T06:17:20Z","timestamp":1615270640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.656407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2021.656407"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.656407","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"article-number":"656407"}}